Table 2.

Molecular profiling of patients on olaparib and placebo—Study 19

Olaparib arm
ST respondersLT responders
All pts (n = 21)HRD score ≥42 (n = 9)HRD score <42 (n = 4)HRD score missing (n = 8)TP53 mutations (n = 12)TP53 WT (n = 4)TP53 missing (n = 5)All pts (n = 32)HRD score ≥42 (n = 21)HRD score <42 (n = 3)HRD score missing (n = 8)TP53 mutations (n = 27)TP53 WT (n = 1)TP53 missing (n = 4)
BRCAm (n = 32)10 (48)6 (67)04 (50)7 (58)1 (25)2 (40)22 (69)18 (86)2 (67)2 (25)20 (74)02 (50)
BRCA WT (n = 19)9 (43)2 (22)3 (75)4 (50)5 (42)3 (75)1 (20)10 (31)3 (14)1 (33)6 (75)7 (26)1 (100)2 (50)
BRCA missing (n = 2)2 (9)1 (11)1 (25)2 (40)
Placebo arm
ST respondersLT responders
All pts (n = 40)HRD score ≥42 (n = 18)HRD score <42 (n = 11)HRD score missing (n = 11)TP53 mutations (n = 29)TP53 WT (n = 1)TP53 missing (n = 10)All pts (n = 5)HRD score ≥42 (n = 4)HRD score <42 (n = 0)HRD score missing (n = 1)TP53 mutations (n = 4)TP53 WT (n = 1)TP53 missing (n = 0)
BRCAm (n = 24)19 (48)13 (72)1 (9)5 (46)16 (55)03 (30)5 (100)4 (100)1 (100)4 (100)1 (100)
BRCA WT (n = 18)18 (45)5 (28)10 (91)3 (27)13 (45)1 (100)4 (40)00000
BRCA missing (n = 3)3 (7)003 (27)003 (30)0
  • NOTE: Data are number (percentage).

  • Abbreviations: Pts, patients; WT, wild-type.